(Reuters) - The U.S. Food and Drug Administration had proposed the
so-called black box warning about anaphylaxis in February but
announced final wording of the new label on Monday.
Xolair, given as an injection and known generically as
omalizumab, is approved to treat adults and adolescents age 12
and above for moderate to severe asthma.
Read more at Reuters.com Government Filings News
so-called black box warning about anaphylaxis in February but
announced final wording of the new label on Monday.
Xolair, given as an injection and known generically as
omalizumab, is approved to treat adults and adolescents age 12
and above for moderate to severe asthma.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment